Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 10/20 | 0.50 |
| ▸ | BTK | Q06187 | 3/20 | 0.49 |
| ▸ | YES1 | P07947 | 5/20 | 0.48 |
| ▸ | FGR | P09769 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | RET | P07949 | 3/20 | 0.47 |
| ▸ | FYN | P06241 | 5/20 | 0.46 |
| ▸ | ABL1 | P00519 | 5/20 | 0.46 |
| ▸ | LYN | P07948 | 4/20 | 0.46 |
| ▸ | EGFR | P00533 | 4/20 | 0.46 |
| ▸ | MTOR | P42345 | 3/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12120631 | 0.88 | SRC (0.47) | CYP1A2KDM4EMAPK1TP53CYP3A4 | |
| SCHEMBL1320126 | 0.79 | SRC (0.55) | CYP1A2KDM4EMAPK1TP53CYP3A4 | |
| SCHEMBL29052195 | 0.78 | SRC (0.59) | CYP1A2KDM4EMAPK1TP53CYP3A4 | |
| SCHEMBL29781148 | 0.78 | SRC (0.59) | CYP1A2KDM4EMAPK1TP53CYP3A4 | |
| SCHEMBL12120638 | 0.78 | KDR (0.57) | SRCKDRRETFYNABL1 | |
| SCHEMBL12120643 | 0.78 | RIPK1 (0.54) | SRCBTKKDRRETFYN | |
| SCHEMBL23997157 | 0.77 | CYP1A2 (0.83) | CYP1A2KDM4EMAPK1TP53CYP3A4 | |
| SCHEMBL29780889 | 0.76 | SRC (0.64) | CYP1A2KDM4EMAPK1TP53CYP3A4 | |
| SCHEMBL29781045 | 0.76 | BTK (0.57) | CYP1A2KDM4EMAPK1TP53CYP3A4 | |
| SCHEMBL24096881 | 0.75 | CYP1A2 (0.68) | CYP1A2KDM4EMAPK1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358720-B1 | FUSED RING HETEROARYL KINASE INHIBITORS | UNIV CALIFORNIA (US) | 2016-03-02 | — | — | EP | disclosed |
| US-8980899-B2 | Methods of inhibiting Ire1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980899-B2 | Methods of inhibiting Ire1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-20 | — | — | US | disclosed |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | XBP1, DNAJC10, HSPA5 | CYP1A2 4387/4885KDM4E 3242/4885MAPK1 2271/4885 |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | CNKSR1, MAP3K20, TTK | CYP1A2 3482/4885KDM4E 1913/4885MAPK1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.